$DT - $EPZM - $OXY - On our trading list with news today or analyst comments with our opinion & trade ideas. Dynatrace upgraded to Buy and price target raised by Goldman. Epizyme received FDA approval - Citi analyst says Buy. Occidental upgraded by SunTrust in a very bullish call.Dynatrace upgraded to Buy from Neutral at Goldman SachsGoldman Sachs analyst Heather Bellini upgraded Dynatrace to Buy from Neutral with a price target of $51, up from $32. The analyst expects the COVID-19 crisis to catalyze both the continued adoption of application performance monitoring and the shift away from on-premise, agent-based monitoring tools to cloud-supported, easily deployed solutions. In this environment, Dynatrace is well positioned given its heritage in application performance monitoring, modern platform, and widespread adoption by and replacements of incumbent monitoring solutions within large, enterprise customers, Bellini tells investors in a research note. She expects the company's subscription revenue and total annual recurring revenue growth to reaccelerate in fiscal 2022.Our Take: Just added this stock to our Tech idea list. Looks like a good growth area currently, although we have some caution as it has already run up a good amount.Epizyme should be bought on any confusion over label, at Citi The FDA yesterday approved Epizyme's Tazverik in Follicular lymphoma with a broad label, which represents a best case scenario, Citi analyst Mohit Bansal tells investors in a research note. It seems investors were confused with the language on the label but the label approved Tazverik in two populations, the analyst points out. Bansal views the approval as an important step for Epizyme, saying it opens a $600M-$700M immediate opportunity and eventually a $1.5B opportunity in second-line. The analyst recommends using any weakness to buy Epizyme and keeps a Buy rating on the shares with a $35 price target.Our Take: Sold on the approval news and maybe some confusion. This is on sale now after the selling here on Friday. Good candidate for Buy/Writes or selling naked Puts.Occidental Petroleum upgraded to Buy from Hold at SunTrustSunTrust analyst Neal Dingmann upgraded Occidental Petroleum to Buy from Hold with a price target of $25, up from $13. The company has "ample" free cash flow and assets to address its elevated leverage and expects it to continue improving its balance sheet through internal and external means, the analyst tells investors in a research note. The potential for "massive" asset sales domestically and internationally is "compelling", Dingmann states, adding that even assuming a "conservative" price deck, he sees over $1B in free cash flow generation this year and about $2.8B in 2021.Our Take: SunTrust is very positive on this one now. If the worst in oil prices is over, it is a good buy or trade under $20. $OXY, Occidental Petroleum Corporation / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Trade Try2BeFunded today! .